365 related articles for article (PubMed ID: 32194562)
41. Cutaneous Lupus Erythematosus in Children.
Tsang V; Leung AKC; Lam JM
Curr Pediatr Rev; 2021; 17(2):103-110. PubMed ID: 33655840
[TBL] [Abstract][Full Text] [Related]
42. Apoptotic signal molecules in skin biopsies of cutaneous lupus erythematosus: analysis using tissue microarray.
Toberer F; Sykora J; Göttel D; Hartschuh W; Werchau S; Enk A; Joos S; Krammer PH; Kuhn A
Exp Dermatol; 2013 Oct; 22(10):656-9. PubMed ID: 24079735
[TBL] [Abstract][Full Text] [Related]
43. Upcoming therapeutic targets in cutaneous lupus erythematous.
Klaeschen AS; Wenzel J
Expert Rev Clin Pharmacol; 2016 Apr; 9(4):567-578. PubMed ID: 26799969
[TBL] [Abstract][Full Text] [Related]
44. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA.
Wenzel J; Uerlich M; Wörrenkämper E; Freutel S; Bieber T; Tüting T
Br J Dermatol; 2005 Nov; 153(5):1011-5. PubMed ID: 16225615
[TBL] [Abstract][Full Text] [Related]
45. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
[TBL] [Abstract][Full Text] [Related]
46. Janus kinase JAK1 maintains the ovarian reserve of primordial follicles in the mouse ovary.
Sutherland JM; Frost ER; Ford EA; Peters AE; Reed NL; Seldon AN; Mihalas BP; Russel DL; Dunning KR; McLaughlin EA
Mol Hum Reprod; 2018 Nov; 24(11):533-542. PubMed ID: 30247637
[TBL] [Abstract][Full Text] [Related]
47. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.
Wenzel J; van Holt N; Maier J; Vonnahme M; Bieber T; Wolf D
J Invest Dermatol; 2016 Jun; 136(6):1281-1283. PubMed ID: 26916391
[No Abstract] [Full Text] [Related]
48. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
49. Hypersensitive IFN Responses in Lupus Keratinocytes Reveal Key Mechanistic Determinants in Cutaneous Lupus.
Tsoi LC; Hile GA; Berthier CC; Sarkar MK; Reed TJ; Liu J; Uppala R; Patrick M; Raja K; Xing X; Xing E; He K; Gudjonsson JE; Kahlenberg JM
J Immunol; 2019 Apr; 202(7):2121-2130. PubMed ID: 30745462
[TBL] [Abstract][Full Text] [Related]
50. The classification and diagnosis of cutaneous lupus erythematosus.
Kuhn A; Landmann A
J Autoimmun; 2014; 48-49():14-9. PubMed ID: 24486120
[TBL] [Abstract][Full Text] [Related]
51. Immunogenetics of cutaneous lupus erythematosus.
Hersh AO; Arkin LM; Prahalad S
Curr Opin Pediatr; 2016 Aug; 28(4):470-5. PubMed ID: 27386968
[TBL] [Abstract][Full Text] [Related]
52. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
[TBL] [Abstract][Full Text] [Related]
53. Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus.
Zahn S; Graef M; Patsinakidis N; Landmann A; Surber C; Wenzel J; Kuhn A
Exp Dermatol; 2014 Jul; 23(7):516-8. PubMed ID: 24758584
[TBL] [Abstract][Full Text] [Related]
54. Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon Loop.
Stannard JN; Reed TJ; Myers E; Lowe L; Sarkar MK; Xing X; Gudjonsson JE; Kahlenberg JM
J Invest Dermatol; 2017 Jan; 137(1):115-122. PubMed ID: 27646883
[TBL] [Abstract][Full Text] [Related]
55. Matrix metalloproteinases as mediators of tissue injury in different forms of cutaneous lupus erythematosus.
Järvinen TM; Kanninen P; Jeskanen L; Koskenmies S; Panelius J; Hasan T; Ranki A; Saarialho-Kere U
Br J Dermatol; 2007 Nov; 157(5):970-80. PubMed ID: 17854363
[TBL] [Abstract][Full Text] [Related]
56. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
57. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus.
Kreuter A; Jaouhar M; Skrygan M; Tigges C; Stücker M; Altmeyer P; Gläser R; Gambichler T
J Am Acad Dermatol; 2011 Jul; 65(1):125-33. PubMed ID: 21353331
[TBL] [Abstract][Full Text] [Related]
58. Lupus dermal fibroblasts are proinflammatory and exhibit a profibrotic phenotype in scarring skin disease.
Shoffner-Beck SK; Abernathy-Close L; Lazar S; Ma F; Gharaee-Kermani M; Hurst A; Dobry C; Pandian D; Wasikowski R; Victory A; Arnold K; Gudjonsson JE; Tsoi LC; Kahlenberg JM
JCI Insight; 2024 Feb; 9(6):. PubMed ID: 38358820
[TBL] [Abstract][Full Text] [Related]
59. JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.
Tuttle KD; Waugh KA; Araya P; Minter R; Orlicky DJ; Ludwig M; Andrysik Z; Burchill MA; Tamburini BAJ; Sempeck C; Smith K; Granrath R; Tracy D; Baxter J; Espinosa JM; Sullivan KD
Cell Rep; 2020 Nov; 33(7):108407. PubMed ID: 33207208
[TBL] [Abstract][Full Text] [Related]
60. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus.
Wang D; Drenker M; Eiz-Vesper B; Werfel T; Wittmann M
Arthritis Rheum; 2008 Oct; 58(10):3205-15. PubMed ID: 18821674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
